Jianjun Chen
Research Subjects
Jianjun Chen has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Colles Price
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637
4 shared publicationsZejuan Li
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
4 shared publicationsStephen Arnovitz
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
3 shared publicationsXi Jiang
Section of Hematology/Oncology, Department of Medicine, and
3 shared publications- Chunjiang He
College of Biomedicine and Health, Hubei Jiangxia Laboratory, Huazhong Agricultural University, Wuhan, China.
2 shared publications Gia-Ming Hong
Section of Hematology/Oncology, Department of Medicine, and
2 shared publications
Latest Publications
- 1 May 2015
- Published by Elsevier in Cancer Genetics
- Vol. 208 (5) , 225-229
The pathological role and prognostic impact of miR-181 in acute myeloid leukemia
- 1 May 2015
- Published by Elsevier in Cancer Genetics
- Vol. 208 (5) , 225-229
The pathological role and prognostic impact of miR-181 in acute myeloid leukemia
- Open Access
- 1 September 2014
- Published by Elsevier in Genes & Diseases
- Vol. 1 (1) , 53-63
MicroRNAs in cancer biology and therapy: Current status and perspectives
- 1 September 2014
- Published by Elsevier in Genes & Diseases
- Vol. 1 (1) , 53-63
Open AccessMicroRNAs in cancer biology and therapy: Current status and perspectives
- Open Access
- 16 May 2014
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 24 (8) , 1296-1307
The dynamics of DNA methylation fidelity during mouse embryonic stem cell self-renewal and differentiation
The faithful transmission of DNA methylation patterns through cell divisions is essential for the daughter cells to retain a proper cell identity. To achieve a comprehensive assessment of methylation fidelity, we implemented a genome-scale hairpin bisulfite sequencing approach to generate methylation data for DNA double strands simultaneously. We show here that methylation fidelity increases globally during differentiation of mouse embryonic stem cells (mESCs), and is particularly high in the promoter regions of actively expressed genes and positively correlated with active histone modification marks and binding of transcription factors. The majority of intermediately (40%–60%) methylated CpG dinucleotides are hemi-methylated and have low methylation fidelity, particularly in the differentiating mESCs. While 5-hmC and 5-mC tend to coexist, there is no significant correlation between 5-hmC levels and methylation fidelity. Our findings may shed new light on our understanding of the origins of methylation variations and the mechanisms underlying DNA methylation transmission.
- 16 May 2014
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 24 (8) , 1296-1307
Open AccessThe dynamics of DNA methylation fidelity during mouse embryonic stem cell self-renewal and differentiation
The faithful transmission of DNA methylation patterns through cell divisions is essential for the daughter cells to retain a proper cell identity. To achieve a comprehensive assessment of methylation fidelity, we implemented a genome-scale hairpin bisulfite sequencing approach to generate methylation data for DNA double strands simultaneously. We show here that methylation fidelity increases globally during differentiation of mouse embryonic stem cells (mESCs), and is particularly high in the promoter regions of actively expressed genes and positively correlated with active histone modification marks and binding of transcription factors. The majority of intermediately (40%–60%) methylated CpG dinucleotides are hemi-methylated and have low methylation fidelity, particularly in the differentiating mESCs. While 5-hmC and 5-mC tend to coexist, there is no significant correlation between 5-hmC levels and methylation fidelity. Our findings may shed new light on our understanding of the origins of methylation variations and the mechanisms underlying DNA methylation transmission.
- Open Access
- 19 August 2013
- Published by Springer Nature in Oncogene
- Vol. 33 (30) , 3887-3893
The role of miR-150 in normal and malignant hematopoiesis
MicroRNAs are a class of small non-coding RNAs that have been implicated to mediate gene regulation in virtually all important biological processes. Recently there is accumulating evidence showing that miR-150 has essential regulatory roles in both normal and malignant hematopoiesis and holds great potential as a therapeutic target in treating various types of hematopoietic malignancies. The purpose of this review is to summarize our current knowledge about the expression patterns, biological functions and regulatory mechanisms of miR-150 in normal and malignant hematopoiesis, and to highlight the important questions to be answered in this burgeoning field.
- 19 August 2013
- Published by Springer Nature in Oncogene
- Vol. 33 (30) , 3887-3893
Open AccessThe role of miR-150 in normal and malignant hematopoiesis
MicroRNAs are a class of small non-coding RNAs that have been implicated to mediate gene regulation in virtually all important biological processes. Recently there is accumulating evidence showing that miR-150 has essential regulatory roles in both normal and malignant hematopoiesis and holds great potential as a therapeutic target in treating various types of hematopoietic malignancies. The purpose of this review is to summarize our current knowledge about the expression patterns, biological functions and regulatory mechanisms of miR-150 in normal and malignant hematopoiesis, and to highlight the important questions to be answered in this burgeoning field.
- 24 June 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (28) , 11511-11516
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia –rearranged leukemia
MicroRNAs (miRNAs), small noncoding RNAs that regulate target gene mRNAs, are known to contribute to pathogenesis of cancers. Acute myeloid leukemia (AML) is a group of heterogeneous hematopoietic malignancies with various chromosomal and/or molecular abnormalities. AML with chromosomal translocations involving the mixed lineage leukemia ( MLL ) gene are usually associated with poor survival. In the present study, through a large-scale, genomewide miRNA expression assay, we show that microRNA-9 (miR-9) is the most specifically up-regulated miRNA in MLL- rearranged AML compared with both normal control and non– MLL -rearranged AML. We demonstrate that miR-9 is a direct target of MLL fusion proteins and can be significantly up-regulated in expression by the latter in human and mouse hematopoietic stem/progenitor cells. Depletion of endogenous miR-9 expression by an appropriate antagomiR can significantly inhibit cell growth/viability and promote apoptosis in human MLL -rearranged AML cells, and the opposite is true when expression of miR-9 is forced. Blocking endogenous miR-9 function by anti-miRNA sponge can significantly inhibit, whereas forced expression of miR-9 can significantly promote, MLL fusion–induced immortalization/transformation of normal mouse bone marrow progenitor cells in vitro. Furthermore, forced expression of miR-9 can significantly promote MLL fusion–mediated leukemogenesis in vivo. In addition, a group of putative target genes of miR-9 exhibited a significant inverse correlation of expression with miR-9 in a series of leukemia sample sets, suggesting that they are potential targets of miR-9 in MLL -rearranged AML. Collectively, our data demonstrate that miR-9 is a critical oncomiR in MLL -rearranged AML and can serve as a potential therapeutic target to treat this dismal disease.
- 24 June 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (28) , 11511-11516
miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia –rearranged leukemia
MicroRNAs (miRNAs), small noncoding RNAs that regulate target gene mRNAs, are known to contribute to pathogenesis of cancers. Acute myeloid leukemia (AML) is a group of heterogeneous hematopoietic malignancies with various chromosomal and/or molecular abnormalities. AML with chromosomal translocations involving the mixed lineage leukemia ( MLL ) gene are usually associated with poor survival. In the present study, through a large-scale, genomewide miRNA expression assay, we show that microRNA-9 (miR-9) is the most specifically up-regulated miRNA in MLL- rearranged AML compared with both normal control and non– MLL -rearranged AML. We demonstrate that miR-9 is a direct target of MLL fusion proteins and can be significantly up-regulated in expression by the latter in human and mouse hematopoietic stem/progenitor cells. Depletion of endogenous miR-9 expression by an appropriate antagomiR can significantly inhibit cell growth/viability and promote apoptosis in human MLL -rearranged AML cells, and the opposite is true when expression of miR-9 is forced. Blocking endogenous miR-9 function by anti-miRNA sponge can significantly inhibit, whereas forced expression of miR-9 can significantly promote, MLL fusion–induced immortalization/transformation of normal mouse bone marrow progenitor cells in vitro. Furthermore, forced expression of miR-9 can significantly promote MLL fusion–mediated leukemogenesis in vivo. In addition, a group of putative target genes of miR-9 exhibited a significant inverse correlation of expression with miR-9 in a series of leukemia sample sets, suggesting that they are potential targets of miR-9 in MLL -rearranged AML. Collectively, our data demonstrate that miR-9 is a critical oncomiR in MLL -rearranged AML and can serve as a potential therapeutic target to treat this dismal disease.
- Open Access
- 14 November 2012
- Published by Impact Journals, LLC in Oncotarget
- Vol. 3 (11) , 1268-1269
miR-150: targeting MLL leukemia
MiR-150: targeting MLL leukemia
- 14 November 2012
- Published by Impact Journals, LLC in Oncotarget
- Vol. 3 (11) , 1268-1269
Open AccessmiR-150: targeting MLL leukemia
MiR-150: targeting MLL leukemia
- 6 November 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (47) , 19397-19402
miR-495 is a tumor-suppressor microRNA down-regulated in MLL -rearranged leukemia
Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic malignancies with variable response to treatment. AMLs bearing MLL (mixed lineage leukemia) rearrangements are associated with intermediate or poor survival. MicroRNAs (miRNAs), a class of small noncoding RNAs, have been postulated to be important gene expression regulators virtually in all biological processes, including leukemogenesis. Through a large-scale, genome-wide miRNA expression profiling assay of 85 human AML and 15 normal control samples, we show that among 48 miRNAs that are significantly differentially expressed between MLL - and non– MLL -rearranged AML samples, only one (miR-495) is expressed at a lower level in MLL -rearranged AML than in non– MLL -rearranged AML; meanwhile, miR-495 is also significantly down-regulated in MLL -rearranged AML samples compared with normal control samples. Through in vitro colony-forming/replating assays and in vivo bone marrow transplantation studies, we show that forced expression of miR-495 significantly inhibits MLL-fusion-mediated cell transformation in vitro and leukemogenesis in vivo. In human leukemic cells carrying MLL rearrangements, ectopic expression of miR-495 greatly inhibits cell viability and increases cell apoptosis. Furthermore, our studies demonstrate that PBX3 and MEIS1 are two direct target genes of miR-495, and forced expression of either of them can reverse the effects of miR-495 overexpression on inhibiting cell viability and promoting apoptosis of human MLL -rearranged leukemic cells. Thus, our data indicate that miR-495 likely functions as a tumor suppressor in AML with MLL rearrangements by targeting essential leukemia-related genes.
- 6 November 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (47) , 19397-19402
miR-495 is a tumor-suppressor microRNA down-regulated in MLL -rearranged leukemia
Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic malignancies with variable response to treatment. AMLs bearing MLL (mixed lineage leukemia) rearrangements are associated with intermediate or poor survival. MicroRNAs (miRNAs), a class of small noncoding RNAs, have been postulated to be important gene expression regulators virtually in all biological processes, including leukemogenesis. Through a large-scale, genome-wide miRNA expression profiling assay of 85 human AML and 15 normal control samples, we show that among 48 miRNAs that are significantly differentially expressed between MLL - and non– MLL -rearranged AML samples, only one (miR-495) is expressed at a lower level in MLL -rearranged AML than in non– MLL -rearranged AML; meanwhile, miR-495 is also significantly down-regulated in MLL -rearranged AML samples compared with normal control samples. Through in vitro colony-forming/replating assays and in vivo bone marrow transplantation studies, we show that forced expression of miR-495 significantly inhibits MLL-fusion-mediated cell transformation in vitro and leukemogenesis in vivo. In human leukemic cells carrying MLL rearrangements, ectopic expression of miR-495 greatly inhibits cell viability and increases cell apoptosis. Furthermore, our studies demonstrate that PBX3 and MEIS1 are two direct target genes of miR-495, and forced expression of either of them can reverse the effects of miR-495 overexpression on inhibiting cell viability and promoting apoptosis of human MLL -rearranged leukemic cells. Thus, our data indicate that miR-495 likely functions as a tumor suppressor in AML with MLL rearrangements by targeting essential leukemia-related genes.
- Open Access
- 1 October 2012
- Published by Bentham Science Publishers Ltd. in Current Genomics
- Vol. 13 (8) , 603-608
Crosstalk Between DNA and Histones: Tet’s New Role in Embryonic Stem Cells
Embryonic stem (ES) cells are characterized by the expression of an extensive and interconnected network of pluripotency factors which are downregulated in specialized cells. Epigenetic mechanisms, including DNA methylation and histone modifications, are also important in maintaining this pluripotency program in ES cells and in guiding correct differentiation of the developing embryo. Methylation of the cytosine base of DNA blocks gene expression in all cell types and further modifications of methylated cytosine have recently been discovered. These new modifications, putative intermediates in a pathway to erase DNA methylation marks, are catalyzed by the ten-eleven translocation (Tet) proteins, specifically by Tet1 and Tet2 in ES cells. Surprisingly, Tet1 shows repressive along with active effects on gene expression depending on its distribution throughout the genome and co-localization with Polycomb Repressive Complex 2 (PRC2). PRC2 di- and tri-methylates lysine 27 of histone 3 (H3K27me2/3 activity), marking genes for repression. In ES cells, almost all gene loci containing the repressive H3K27me3 modification also bear the active H3K4me3 modification, creating “bivalent domains” which mark important developmental regulators for timely activation. Incorporation of Tet1 into the bivalent domain paradigm is a new and exciting development in the epigenetics field, and the ramifications of this novel crosstalk between DNA and histone modifications need to be further investigated. This knowledge would aid reprogramming of specialized cells back into pluripotent stem cells and advance understanding of epigenetic perturbations in cancer.
- 1 October 2012
- Published by Bentham Science Publishers Ltd. in Current Genomics
- Vol. 13 (8) , 603-608
Open AccessCrosstalk Between DNA and Histones: Tet’s New Role in Embryonic Stem Cells
Embryonic stem (ES) cells are characterized by the expression of an extensive and interconnected network of pluripotency factors which are downregulated in specialized cells. Epigenetic mechanisms, including DNA methylation and histone modifications, are also important in maintaining this pluripotency program in ES cells and in guiding correct differentiation of the developing embryo. Methylation of the cytosine base of DNA blocks gene expression in all cell types and further modifications of methylated cytosine have recently been discovered. These new modifications, putative intermediates in a pathway to erase DNA methylation marks, are catalyzed by the ten-eleven translocation (Tet) proteins, specifically by Tet1 and Tet2 in ES cells. Surprisingly, Tet1 shows repressive along with active effects on gene expression depending on its distribution throughout the genome and co-localization with Polycomb Repressive Complex 2 (PRC2). PRC2 di- and tri-methylates lysine 27 of histone 3 (H3K27me2/3 activity), marking genes for repression. In ES cells, almost all gene loci containing the repressive H3K27me3 modification also bear the active H3K4me3 modification, creating “bivalent domains” which mark important developmental regulators for timely activation. Incorporation of Tet1 into the bivalent domain paradigm is a new and exciting development in the epigenetics field, and the ramifications of this novel crosstalk between DNA and histone modifications need to be further investigated. This knowledge would aid reprogramming of specialized cells back into pluripotent stem cells and advance understanding of epigenetic perturbations in cancer.